期刊
BIOMEDICINES
卷 10, 期 12, 页码 -出版社
MDPI
DOI: 10.3390/biomedicines10123287
关键词
scabies; impetigo; manuka oil; abametapir; ivermectin; beta-triketones; Staphylococcus aureus; Streptococcus pyogenes; Streptococcus dysgalactiae subsp; equisimilis; Acinetobacter baumannii
资金
- National Health and Medical Research Council of Australia
- DIORAPHTE-funded Research Programme for Skin-related Neglected Tropical Diseases [APP1154805, APP1163354]
- [20020403]
This study investigates the antimicrobial potential of current and emerging scabicides and finds that both abametapir and manuka oil have antimicrobial properties against common scabies-associated bacteria. The current scabicide ivermectin also shows some antimicrobial activity.
Scabies is a dermatological disease found worldwide. Mainly in tropical regions, it is also the cause of significant morbidity and mortality due to its association with potentially severe secondary bacterial infections. Current treatment strategies for scabies do not consider the role of opportunistic bacteria, and here we investigate whether current and emerging scabicides can offer any anti-bacterial protection. Using the broth microdilution method, we examined antimicrobial potential of the current scabicide ivermectin and emerging scabies treatments: abametapir, manuka oil, and its individual beta-triketones. Our results demonstrate that the two novel scabicides abametapir and manuka oil have antimicrobial properties against common scabies-associated bacteria, specifically Staphylococcus aureus, Streptococcus pyogenes, Streptococcus dysgalactiae subsp. equisimilis and Acinetobacter baumannii. The current scabicide ivermectin offers some antimicrobial activity and is capable of inhibiting the growth aforementioned bacteria. This research is important as it could help to inform future best treatment options of scabies, and scabies-related impetigo.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据